Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
RNAC
STRONG SELLCartesian Therapeutics, Inc. · Healthcare · United States · $232M · Avg Vol: $2M/d
COMPANY DESCRIPTION
Cartesian Therapeutics, Inc. is a clinical-stage biotechnology company developing mRNA cell therapies for autoimmune diseases and cancer. The company utilizes its proprietary RNA cell therapy platform to create highly engineered, autologous cell therapies that avoid genetic modification and minimize manufacturing complexity. This innovative approach to cell therapy, particularly its focus on autoimmune indications, distinguishes Cartesian in the competitive biotechnology landscape by offering a potentially safer and more scalable therapeutic modality.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 110.8M | 26.0M | 38.9M | 2.8M | -70.7% | 1.8M | 0.6M | 0.4M | -62.1% |
| EPS | 1.25 | -9.14 | -4.48 | -5.02 | — | -5.74 | -3.35 | -2.68 | — |
| Shares | 29.4M | 29.4M | 25.8M | 26.0M | -11.5% | 29.4M | — | — | — |
| Debt | 37.9M | 11.0M | 14.0M | 12.7M | -30.6% | 11.9M | — | — | — |
| Equity | 93.8M | -440.2M | -6.8M | -126.2M | — | — | — | — | — |
| Op CF | -31.6M | -51.2M | -23.7M | -73.9M | — | -73.0M | — | — | — |
| Inv CF | -15.0M | 34.6M | -8.7M | -5.5M | — | — | — | — | — |
| Fin CF | 39.2M | -13.1M | 168.4M | -8.1M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of RNAC are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| RNAC | Cartesian Therapeutics, Inc.(you) | $232M | 12 | STRONG SELL |
| TARA | Protara Therapeutics, Inc. | $226M | 12 | STRONG SELL |
| OTLK | Outlook Therapeutics, Inc. | $263M | 12 | STRONG SELL |
| IRD | Opus Genetics, Inc. | $254M | 13 | STRONG SELL |
| SRZN | Surrozen, Inc. | $229M | 15 | STRONG SELL |
| NAUT | Nautilus Biotechnology, Inc. | $215M | 14 | STRONG SELL |
| FULC | Fulcrum Therapeutics, Inc. | $248M | 15 | STRONG SELL |
| NBP | NovaBridge Biosciences | $205M | 11 | STRONG SELL |
| GALT | Galectin Therapeutics Inc. | $229M | 9 | STRONG SELL |
| AVXL | Anavex Life Sciences Corp. | $222M | 9 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.6%